CCR3 and Choroidal Neovascularization
2011

The Role of CCR3 in Choroidal Neovascularization

publication Evidence: high

Author Information

Author(s): Li Yiwen, Huang Deqiang, Xia Xin, Wang Zhengying, Luo Lingyu, Wen Rong

Primary Institution: Bascom Palmer Eye Institute, University of Miami Miller School of Medicine

Hypothesis

Does CCR3 play a significant role in the development of choroidal neovascularization (CNV)?

Conclusion

CCR3 does not play a significant role in CNV development, while targeting VEGF-A and mTOR is effective in suppressing CNV.

Supporting Evidence

  • Blocking CCR3 did not inhibit CNV development in both rat and mouse models.
  • VEGF-A neutralizing antibodies significantly suppressed CNV development.
  • Rapamycin treatment also effectively inhibited CNV development.

Takeaway

The study found that blocking a specific protein called CCR3 doesn't help with a type of eye disease that causes vision loss, but blocking another protein called VEGF-A does help.

Methodology

The study used a Matrigel-induced CNV model in rats and mice to assess the effects of CCR3 antagonists and neutralizing antibodies on CNV development.

Limitations

The study did not explore other potential roles of CCR3 in different contexts or conditions.

Participant Demographics

Adult Sprague Dawley rats and BALB/c mice were used in the experiments.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0017106

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication